Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
Executive Summary
The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia
You may also be interested in...
Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data
A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs
Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data
A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs
Cymbalta Advisory Committee Review In Chronic Pain Now Set For August
Rescheduled panel meeting could include discussion of statistical methods for dealing with missing patient data and safe use in a significantly broader population.